Risk factors

MBX Biosciences has incurred significant cumulative losses and net losses of $61.9 million for 2024 and $32.6 million for 2023. The company relies heavily on early-stage clinical candidates like canvuparatide and MBX 1416 requiring substantial additional funding. Operations face severe regulatory risks including unpredictable FDA approvals and specialized cold-chain logistics requirements.

Company faces heavy concentration in metallurgical coal for steel production, operating primarily in the Appalachian basin.

As an early-stage genome editing company with $248.3M in cash and a $223.0M accumulated deficit, risks center on unproven technology, substantial funding needs, and clinical trial execution.

Meridian Corp's risk profile is dominated by traditional banking exposures including interest rate volatility, credit and real estate loan concentrations, and intense local competition.

NewtekOne faces intense regulatory oversight from the FDIC, OCC, and Federal Reserve as a newly minted financial holding company and bank parent. The business is heavily dependent on SBA 7(a) lending, government programs, and secondary market sales. Strategic risks stem from interest rate fluctuations, credit defaults in small business loans, and execution of new banking operations following the BDC withdrawal.

Revenue depends heavily on oil and gas industry expenditures and a single customer representing 54 percent of 2024 revenue. Month-to-month rental agreements cover half of all compressor units and a quarter of rented horsepower. The credit facility provides a $300 million borrowing commitment with variable interest rates and restrictive financial covenants.

NRC Health relies heavily on renewable healthcare client contracts and survey data collection, facing intense competition and regulatory exposure.

Concentration of commercial real estate loans and geographic reliance on the New York metropolitan area dominate risks. Wealth management operations and municipal deposits expose the bank to specific regulatory and liquidity risks.

OPAL Fuels is heavily exposed to regulatory policy changes and fluctuating market prices for renewable energy environmental attributes.

Pacific Biosciences faces ongoing net losses, negative cash flow, and debt burdens requiring cost reduction initiatives. The business relies on complex manufacturing of sequencing systems like Revio and Onso, facing intense competition and geopolitical risks in China and Taiwan. Patent litigation and complex intellectual property challenges significantly threaten the company's competitive advantage.

Concentrated reliance on limited paper mills for kraft paper creates supply chain and cost vulnerability. Heavy dependence on e-commerce end-users ties demand to broader consumer preference shifts. Extensive global footprint exposes operations to foreign currency, geopolitical, and regulatory risks.

PagerDuty faces persistent operating losses, accumulating $595.2 million in deficit as of January 31, 2025. Growth relies heavily on a single incident management product and expanding international sales. Dependence on AWS and third-party integrations exposes operations to external disruptions.